Review
Biochemistry & Molecular Biology
Hua-Min Zhang, Shuo Yuan, Huan Meng, Xiao-Ting Hou, Jiao Li, Jia-Chen Xue, You Li, Qi Wang, Ji-Xing Nan, Xue-Jun Jin, Qing-Gao Zhang
Summary: Inflammatory bowel disease (IBD) is a chronic, relapsing disease that greatly affects patients' quality of life. Stem cell therapy has shown potential to improve the clinical disease activity of patients with refractory IBD when conventional treatments are not effective, but its safety and long-term efficacy need further evaluation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Andrea Cassinotti, Francesco Passamonti, Sergio Segato
Summary: Cell-based therapies have been explored in immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD). The most studied treatment in IBD involves stem cells, with recent studies also focusing on regulatory cells such as T-reg and Tr1 cells. Preclinical research is also being conducted on induced pluripotent stem cells in animal models related to colitis.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Multidisciplinary Sciences
Guopu Chen, Fengyuan Wang, Min Nie, Hui Zhang, Han Zhang, Yuanjin Zhao
Summary: The newly developed roe-inspired microcapsules, providing sufficient nutrient supply and maintaining the functions of mesenchymal stem cells through core-shell structure, have the potential for clinical application in treating inflammatory bowel disease.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Review
Immunology
Qihang Hou, Jingxi Huang, Hammed Ayansola, Hori Masatoshi, Bingkun Zhang
Summary: The mammalian intestine is the largest immune organ, containing intestinal stem cells (ISC), differentiated epithelial cells, and gut resident-immune cells. Inflammatory bowel disease (IBD) threatens intestinal integrity and the continuous renewal of intestinal mucosal epithelium relies on ISC. Targeting inflamed mucosa healing may improve clinical symptoms and disease recurrence in IBD patients. Recent findings suggest that immune cells and cytokines play critical roles in ISC and intestinal epithelium regeneration, paving the way for new therapeutic approaches such as ISC transplantation. Integration of biological agents and ISC transplantation could revolutionize future therapy for IBD patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Cell & Tissue Engineering
Yusuke Wakisaka, Shinya Sugimoto, Toshiro Sato
Summary: This review discusses the application of adult tissue-derived organoids culture technology to elucidate the pathogenesis of IBD and to develop novel therapies, including regenerative treatments.
Review
Pharmacology & Pharmacy
Badr Al-Bawardy, Raina Shivashankar, Deborah D. Proctor
Summary: This review discusses novel therapeutic targets for inflammatory bowel diseases, including selective JAK inhibitors, anti-interleukin drugs, leukocyte migration inhibitors, and other small molecules currently in development.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Immunology
Zhengping Che, Ziyu Ye, Xueying Zhang, Bihua Lin, Weiqing Yang, Yanfang Liang, Jincheng Zeng
Summary: Inflammatory bowel diseases (IBDs) are a group of chronic inflammatory disorders of the gastrointestinal tract. Current treatments are not fully curative and often lead to relapse. Mesenchymal stem/stromal cells (MSCs), with their multipotent differentiation and immunomodulatory capabilities, show potential for the treatment of IBDs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Cheng-Mei Tian, Yuan Zhang, Mei-Feng Yang, Hao-Ming Xu, Min-Zheng Zhu, Jun Yao, Li-Sheng Wang, Yu-Jie Liang, De-Feng Li
Summary: Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract. Stem cells (SCs) have shown potential in treating IBD due to their ability to modulate immunity, suppress inflammation, and promote tissue repair. This review summarizes the current research on the safety and efficacy of SC-based therapy for IBD and discusses potential mechanisms and engineering strategies to enhance the therapeutic effects of SCs. It also highlights the current limitations and future perspectives of SC-related therapy for IBD.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Jun Ho Lee, Jan Lotvall, Byong Seung Cho
Summary: This study evaluated the therapeutic potential of extracellular vesicles released by adipose-tissue-derived mesenchymal stem cells (ASC-EXOs) in a mouse model of inflammatory bowel disease (IBD). The results showed that the route of administration, number of injections, and dosage of ASC-EXOs significantly affected their effectiveness as a therapeutic agent for IBD. Combination therapy of ASC-EXOs and anti-IL-12 showed potential benefits in reducing the disease activity index (DAI).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Huldani Huldani, Ria Margiana, Fawad Ahmad, Maria Jade Catalan Opulencia, Mohammad Javed Ansari, Dmitry Olegovich Bokov, Nargiza N. Abdullaeva, Homayoon Siahmansouri
Summary: Inflammatory bowel disease (IBD) is caused by various pathophysiologic pathways and immune-pathologic etiologies. Mesenchymal Stem Cells (MSCs) have been suggested as a potential treatment for IBD due to their immune regulatory functions. Clinical trials using MSCs from bone marrow, umbilical cord, and adipose tissue have shown promising results in terms of safety. However, further research is needed to obtain more reliable results and more support from laboratory evidence.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Cell & Tissue Engineering
Theresa Louise Boye, Casper Steenholdt, Kim Bak Jensen, Ole Haagen Nielsen
Summary: The pathogenesis of inflammatory bowel diseases (IBD) involves genetic predisposition, environmental factors, and dysregulated intestinal immune response. Treatment targets focus on mucosal and histological healing, but future therapies may involve molecular restoration using stem cell therapy.
Article
Multidisciplinary Sciences
Robin J. Dart, Iva Zlatareva, Pierre Vantourout, Efstathios Theodoridis, Ariella Amar, Shichina Kannambath, Philip East, Timothy Recaldin, John C. Mansfield, Christopher A. Lamb, Miles Parkes, Peter M. Irving, Natalie J. Prescott, Adrian C. Hayday
Summary: This study investigates the presence of tissue-protective gamma delta T cells in the human colon and their association with inflammatory bowel disease. The researchers identified a specific subset of these cells that were diminished and dysregulated in patients with the disease. Additionally, they found that restoration of these cells was associated with remission of the disease. Furthermore, they discovered that individuals with a genetic mutation associated with these cells had an increased risk of developing a severe form of Crohn's disease. These findings highlight the importance of these unique cells in limiting the progression of tissue-damaging diseases.
Article
Agriculture, Dairy & Animal Science
Jose Ignacio Cristobal, Francisco Javier Duque, Jesus Maria Uson-Casaus, Patricia Ruiz, Esther Lopez Nieto, Eva Maria Perez-Merino
Summary: The study evaluated the feasibility and effects of combined application of stem cells and prednisone in dogs with IBD for the first time. Results demonstrated that stem cell transplantation significantly and safely improved the disease condition in dogs with IBD, irrespective of prednisone treatment. The beneficial effects of the therapy were stable and long lasting, and allowed for a reduction or elimination of steroid dosage.
Review
Immunology
Xiaowen Zheng, Yi Zhu, Zihan Zhao, Ying Chu, Wenjing Yang
Summary: Inflammation is a characteristic symptom of many diseases, and this review summarizes the changes and mechanisms of amino acids in inflammatory bowel disease and other inflammatory diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Chao Liu, Yuhong Jiang, Ganglei Liu, Zhushu Guo, Qianqian Jin, Dongju Long, Weihan Zhou, Ke Qian, Hua Zhao, Kuijie Liu
Summary: This study found that PPARGC1A was downregulated in DSS-induced colitis and DSS-stimulated colonic epithelial cells, and PDT treatment could upregulate PPARGC1A expression. Knockdown of PPARGC1A could attenuate the therapeutic effects of PDT on DSS-induced colitis and DSS-stimulated colonic epithelial cells.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Cell & Tissue Engineering
Rosario Hervas-Salcedo, Maria Fernandez-Garcia, Miriam Hernando-Rodriguez, Oscar Quintana-Bustamante, Jose-Carlos Segovia, Marcio Alvarez-Silva, Mariano Garcia-Arranz, Pablo Minguez, Victoria del Pozo, Marta Rodriguez de Alba, Damian Garcia-Olmo, Carmen Ayuso, Maria Luisa Lamana, Juan A. Bueren, Rosa Maria Yanez
Summary: The transient co-expression of CXCR4 and IL10 enhances the therapeutic potential of MSCs in a local inflammation mouse model, indicating that mRNA-modified cells may be a new step towards more efficient cell therapies for inflammatory diseases.
STEM CELL RESEARCH & THERAPY
(2021)
Review
Cell Biology
David Garcia-Bernal, Mariano Garcia-Arranz, Rosa M. Yanez, Rosario Hervas-Salcedo, Alfonso Cortes, Maria Fernandez-Garcia, Miriam Hernando-Rodriguez, Oscar Quintana-Bustamante, Juan A. Bueren, Damian Garcia-Olmo, Jose M. Moraleda, Jose C. Segovia, Agustin G. Zapata
Summary: MSCs are widely used in advanced therapies for various purposes, mainly related to inflammatory processes. Despite their demonstrated efficacy in preclinical models and early clinical trials, there are still controversies regarding their specific phenotype, delivery methods, and varied cell products. Strategies for bioengineering MSCs are being explored to enhance their properties and functional capabilities.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Immunology
Raquel Fernandez-Perez, Mercedes Lopez-Santalla, Rebeca Sanchez-Dominguez, Omaira Alberquilla, Irene Gutierrez-Canas, Yasmina Juarranz, Juan A. Bueren, Marina Garin
Summary: Galectin-1 is a beta-galactoside-binding lectin that plays a crucial role in regulating intestinal inflammation by modulating T cell reactivity, affecting the development and severity of colitis. Studies have shown that deficiency of endogenous galectin-1 leads to enhanced inflammatory responses, characterized by altered Th17/Th1 profiles and increased regulatory T cells in the colon lamina propria. Additionally, adoptive transfer of wild type regulatory T cells can alleviate exacerbated intestinal inflammation in galectin-1 deficient mice.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Mercedes Lopez-Santalla, Juan A. Bueren, Marina Garin
Summary: Research analyzed key aspects and new approaches of using mesenchymal stem cell therapy for rheumatoid arthritis, showing promise for improving treatment efficacy.
Article
Medicine, Research & Experimental
Cristina Mesa-Nunez, Carlos Damian, Maria Fernandez-Garcia, Begona Diez, Gayatri Rao, Jonathan D. Schwartz, Ken M. Law, Julian Sevilla, Paula Rio, Rosa Yanez, Juan A. Bueren, Elena Almarza
Summary: Gene therapy was shown to effectively correct the phenotype of mice with severe LAD-I, providing preclinical evidence for its safety and efficacy. Ectopic expression of hCD18 did not alter the characteristics of healthy donor hematopoietic stem cells and their progeny, and the repopulating properties of these cells were preserved. Transduction of CD34+ cells from severe LAD-I patients restored the expression of 02-integrins.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2022)
Article
Immunology
Mercedes Lopez-Santalla, Carmen Conde, Angela Rodriguez-Trillo, Marina Garin
Summary: Rheumatoid arthritis is an autoimmune disease with unresolved treatment issues. Mesenchymal stem cell therapy has emerged as a potential alternative, but its effectiveness may vary in different arthritis models.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Sebastian M. Siegner, Laura Ugalde, Alexandra Clemens, Laura Garcia-Garcia, Juan A. Bueren, Paula Rio, Mehmet E. Karasu, Jacob E. Corn
Summary: This article presents a gene editing strategy using base editors to correct pathogenic gene mutations in Fanconi Anemia patients' stem cells. The experimental results demonstrate that optimized base editing can restore gene expression and function, indicating the therapeutic potential for Fanconi Anemia.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Rosario Hervas-Salcedo, Maria Fernandez-Garcia, Miriam Hernando-Rodriguez, Cristian Suarez-Cabrera, Juan A. Bueren, Rosa M. Yanez
Summary: Previous clinical trials have shown that mesenchymal stromal cells (MSCs) can modulate graft versus host disease (GvHD) after allogeneic hematopoietic transplantation. Adipose tissue derived-human MSCs (Ad-MSCs) were engineered to express CXCR4 and IL-10, resulting in CXCR4-IL10-MSCs with enhanced migration and immunomodulatory properties. In vitro and in vivo studies demonstrated the improved therapeutic effects of CXCR4-IL10-MSCs, suggesting their potential as a new generation of MSCs for GvHD treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Marta Garcia, Jose Bonafont, Jesus Martinez-Palacios, Rudan Xu, Giandomenico Turchiano, Stina Svensson, Adrian J. Thrasher, Fernando Larcher, Marcela Del Rio, Ruben Hernandez-Alcoceba, Marina Garin, Angeles Mencia, Rodolfo Murillas
Summary: In this study, adenoviral vectors were developed for CRISPR-Cas9 delivery to remove exon 80 of COL7A1, leading to successful treatment of skin lesions in patients with recessive dystrophic epidermolysis bullosa (RDEB).
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT
(2022)
Letter
Biochemistry & Molecular Biology
Thomas Fox, Juan Bueren, Fabio Candotti, Alain Fischer, Alessandro Aiuti, Arjan Lankester, Michael AGORA Initiative, Michael Albert, Maria Ester Bernardo, Marina Cavazzana, Stephan Ehl, Benedicte Neven, Johan Prevot, Axel Schambach, Julian Sevilla, Adrian Thrasher, Rob Wynn, Claire Booth
Review
Biotechnology & Applied Microbiology
Juan A. Bueren, Alberto Auricchio
Summary: The development of viral vectors and recombinant DNA technology has made gene therapy a viable option for inherited and acquired diseases. Despite significant progress, there are still limitations and challenges in the clinical application of gene therapy.
HUMAN GENE THERAPY
(2023)
Article
Immunology
Juan Pablo Medina, Ismael Bermejo-Alvarez, Sandra Perez-Baos, Rosa Yanez, Maria Fernandez-Garcia, Damian Garcia-Olmo, Aranzazu Mediero, Gabriel Herrero-Beaumont, Raquel Largo
Summary: This study investigated the effect of Adipose-Derived Mesenchymal Stem Cells (Ad-MSC) on acute joint inflammation in rabbits with gouty arthritis. The results showed that Ad-MSC accelerated the resolution of inflammation, promoted the formation of M2 macrophages, inhibited NLRP3 and NF-kB activity, and increased the production of anti-inflammatory cytokines IL-10 and TGF-β. Therefore, Ad-MSC could be a pharmacological alternative for patients who cannot undergo conventional treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Meeting Abstract
Biotechnology & Applied Microbiology
R. Hervas-Salcedo, M. Fernandez-Garcia, M. Hernando-Rodriguez, J. A. Bureren, R. M. Yanez
HUMAN GENE THERAPY
(2022)
Meeting Abstract
Immunology
Mercedes Lopez Santalla, Miriam Hernando Rodriguez, Miguel Angel Martin, Rosa Maria Yanez, Juan Antonio Bueren, Marina Inmaculada Garin
EUROPEAN JOURNAL OF IMMUNOLOGY
(2021)